BEERSE, Belgium, December 4 /PRNewswire/ -- Ortho Biotech Oncology Research Development, a division of Janssen Pharmaceutica N.V., today announced that data related to several of its oncology compounds will be presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana, from December 5th to December 8th, 2009.
As an organization, we are very committed to meeting the needs of patients with hematologic disorders and malignancies, and to advancing science in this area, said Peter Ho, Head of Development for Oncology, Ortho Biotech Oncology Research Development. In this exciting time in clinical research, we are pleased that these data are being presented at ASH.
These following clinical studies, selected for oral or poster presentation, were sponsored either by Ortho Biotech Oncology Research Development or its research partners, including: Johnson Johnson Pharmaceutical Research Development, LLC, Centocor Ortho Biotech Inc., Centocor RD, Inc. and Janssen-Cilag GmbH. (Note that these studies are grouped by compound and listed in date order within each section.):
VELCADE(R) (bortezomib) - VELCADE, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial) (Abstract 131) Oral and Poster Abstracts Oral Session: Myeloma - Therapy, excluding Transplantation: Combination Therapy for Newly Diagnosed Multiple Myeloma Sunday, December 6, 2009, 5:30 PM CST, Hall F (Ernest N. Morial Convention Center) Authors: H. Einsele, P. Liebisch, C. Langer, et al. - Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial (Abstract 2312) Oral and Poster Abstracts Poster Session: Clinical Results - Autologous Transplantation Poster II Sunday, December 6, 2009, 6:00 -8:00 PM CST, Hall E (Ernest N. Morial Convention Center), Poster Board II-289 Authors: H. Ludwig, L. Viterbo, R. Greil, et al. - Bortezomib Plus Melphalan-Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan-Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use (Abstract 3859) Oral and Poster Abstracts Poster Session: Myeloma - Therapy, excluding Transplantation Poster III Monday, December 7, 2009, 6:00 -8:00 PM CST, Hall E (Ernest N. Morial Convention Center), Poster Board III-795 Authors: MV. Mateos, P. G. Richardson, R. Schlag, et al. - Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Multiple Myeloma (Abstract 3875) Oral and Poster Abstracts Poster Session: Myeloma - Therapy, excluding Transplantation Poster III Monday, December 7, 2009, 6:00 -8:00 PM CST, Hall E (Ernest N. Morial Convention Center), Poster Board III-811 Authors: D. S. Ricci, R. Favis, Y. Sun, et al. VELCADE(R) / DOXIL(R) (doxorubicin HCl liposome injection) - Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin (Abstract 109) Oral and Poster Abstracts Oral Session: Molecular Pharmacology, Drug Resistance I Sunday, December 6, 2009, 4:30 PM CST, R06-R09 (Ernest N. Morial Convention Center) Authors: G. Buda, D. Ricci, N. Cohen, et al.
VELCADE is the first proteasome inhibitor to receive worldwide regulatory approval for the treatment of multiple myeloma (MM). In 2005, VELCADE was approved in the European Union for MM after relapse and has now received approval from the European Commission in combination with melphalan and prednisone for the treatment of patients with previously untreated MM who are not eligible for high-dose chemotherapy with bone marrow transplant.
Notes for Editors:
VELCADE is a medicine used to treat the blood based cancer known as multiple myeloma. It contains an active substance called bortezomib and is the first in a new class of medicines known as proteasome inhibitors. Proteasomes are present in all cells and play an important role in controlling cell function, growth and also how cells interact with the other cells around them. VELCADE reversibly interrupts the normal working of cell proteasomes causing myeloma cancer cells to stop growing and die.(1)
For further information on VELCADE see the EU Summary of Product Characteristics (SmPC): http://emc.medicines.org.uk/document.aspx?documentId=17109
Janssen-Cilag is one of the world's leading research-based pharmaceutical companies, with operations throughout the world. In the UK, Janssen-Cilag Limited employs more than 500 people.
The company is committed to discovering and delivering innovative medicines for diseases of high unmet medical need and has introduced a range of treatments that make an important difference to the lives of patients with serious health conditions.
Key areas of activity include; psychiatry; neurology; oncology; immunology; HIV; antibiotics; pain management; fungal diseases/dermatology; gastroenterology and women's health.
Key products include Risperdal(R) (schizophrenia, bipolar disorder), Risperdal(R) Consta(R) (schizophrenia), Concerta(R) XL (ADHD), Velcade(R) (oncology), Prezista(R) Intelence(R) (HIV), Stelara(R) (psoriasis), Topamax(R) (epilepsy, migraine), Doribax(R) (antibiotics), Daktarin(R) (anti-fungal), Sporanox (anti-fungal), Durogesic(R) DTrans(R) (pain management), Pariet(R) (gastroenterology), Cilest(R) and Evorel(R) (women's health).
Medicines developed by Janssen-Cilag are used to treat around 1,500 million patients worldwide every year.
Janssen-Cilag is part of the Johnson Johnson family of companies, which comprises around 250 operating companies throughout the world and employs approximately 120,000 people in 57 countries, 6,000 of them in the UK. Johnson Johnson is the world's most comprehensive and broadly based manufacturer of health care products and related services.
More information can be found at www.janssen-cilag.co.uk
Reference: EU Summary of Product Characteristics (SmPC): http://emc.medicines.org.uk/document.aspx?documentId=17109
SOURCE: Ortho Biotech Oncology Research SOURCE: Development
CONTACT: Jennifer Tear, Communications EMEA, +32-146-026-38